Dsm-Firmenich’s two HMO ingredients approved in China for early-life nutrition
The ingredients are GlyCare 2’-fucosyllactose (2’-FL) and GlyCare lacto-N-neotetraose (LNnT).
Two human milk oligosaccharide (HMO) ingredients from Dsm-Firmenich (Kaiseraugst, Switzerland) are now approved for infant nutrition in China. The ingredients are GlyCare 2’-fucosyllactose (2’-FL) and GlyCare lacto-N-neotetraose (LNnT).
“This approval is a significant milestone as it will create new opportunities for innovation in the field of early-life nutrition and make the unique benefits of HMOs accessible to infants and young children in China," the firm's press release states.
The approval means that 2’-FL HMO can be included as an ingredient in infant formula, formula for elder infants and young children, infant formula for special medical purposes, and formulated milk powder, at usage levels between 0.7 and 2.4 g/L. Meanwhile, LNnT can be used in those same applications at a dose of 0.2-0.6 g/L.
The company adds that 2’-FL and LNnT are currently the only two HMO ingredients approved in the Chinese market. “HMOs are the next important ingredient for bringing the composition of infant formula closer to breast milk, the gold standard of infant nutrition, and this approval ensures that all infants in China now have access to this important nutrient,” said James Young, vice president of early life nutrition at Dsm-Firmenich, in a press release.
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
